VIR Dana dhuwit perusahaan Vir Bio

Logo grafis Vir Biotechnology (VIR)

Vir Biotechnology, Inc. (VIR) relies on the expertise of its top management in virology and the transparency of its research. Production and testing are outsourced to external contractors. The growth of the hepatitis patient base is driven by partnerships with industry behemoths. The amount of cash resources helps assess the business's financial stability, while the 0.46 mark indicates the current liquidity reserve level on the chart.

Vir Biotechnology Inc - Gunggung dana dhuwit perusahaan VIR (periode 04.07.2022 - 21.11.2026)

Rincian metrik lan analitis perusahaan Vir Biotechnology (VIR)

- kuotasi lan prakiraan analis:
Pambiji fundamental:VIR Vir Biotechnology
Produk merek vir.bio

This indicator measures the volume of undistributed capital in accounts, determining the business's ability to cover operating expenses and avoid cash flow gaps without incurring external debt. By analyzing the cash trajectory, investors assess the financial stability of Vir Biotechnology, Inc. (VIR) as it pivots its portfolio from COVID-19 drugs toward the development of innovative antibodies against hepatitis B and Delta.